India, June 16 -- Sun Pharmaceutical Industries has informed that the US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited's Halol facility (Gujarat, India) from 02 June to 13 June 2025. At the conclusion of the inspection, the US FDA issued a Form-483, with 8 observations.
Published by HT Digital Content Services with permission from Pivotal Sources....